ALR Technologies to Acquire CGM Medical Technology for $45 Million and 200 Million Shares

ALR Technologies has entered into a letter of intent to acquire 100 percent of CGM Medical Technology Singapore and the assets of CGM Medical Technology Shenzhen for a total of 200 million ordinary shares and 45 million US dollars, announced in a press release.

The acquisition will give ALR Technologies full ownership of the intellectual property and technology used in its GluCurve Pet continuous glucose monitor and upcoming human health devices. The company plans to build a manufacturing facility in the Johor-Singapore Special Economic Zone using CGM Medical Singapore’s resources once the deal is completed.

Under the letter of intent, CGM Medical Singapore will be purchased for 200 million shares and a 40 million dollar unsecured, non-interest-bearing promissory note payable through 25 percent of ALR Technologies’ free cash flow after the facility reaches production levels of 500,000 units per month. The Shenzhen assets will be acquired for up to 5 million dollars, with 1 million paid at closing and the remainder through 25 percent of free cash flow once production capacity reaches 300,000 units per month.

ALR Technologies expects to finalize the definitive agreement for CGM Medical Singapore by July 31, 2026, with completion by August 31, 2026. The Shenzhen transaction is expected to close by January 31, 2027, following completion of due diligence, regulatory approvals, and production milestones.